John Whitesides

UCB Pharma (United States) — United States

Medicine · Health Sciences

19h-index1.6kcitations39works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epilepsy research and treatment(26), Pharmacological Effects and Toxicity Studies(22), Neuroscience and Neuropharmacology Research(12), Parkinson's Disease Mechanisms and Treatments(10), Neurological disorders and treatments(6)

Publications39 total

Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis
Epilepsy & Behavior·2020· 49 citedOpen Access
Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program
Epilepsy Research·2018· 22 citedOpen Access
Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies
Epilepsy Research·2018· 22 cited
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis
Epilepsy & Behavior·2018· 18 citedOpen Access
A review of the pharmacology and clinical efficacy of brivaracetam
Clinical Pharmacology Advances and Applications·2018· 98 citedOpen Access
Long-term retention rates for antiepileptic drugs: A review of long-term extension studies and comparison with brivaracetam
Epilepsy Research·2017· 33 cited
Erratum to “Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study” [Epilepsy Res. 131 (2017) 70–75]
Epilepsy Research·2017
Efficacy of adjunctive brivaracetam in patients with secondarily generalized tonic-clonic seizures at baseline: pooled results from long-term follow-up studies (P6.238)
Neurology·2017
Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study
Epilepsy Research·2017· 32 citedOpen Access
Time to onset of sustained ≥50% responder status in patients with focal (partial‐onset) seizures in three phase III studies of adjunctive brivaracetam treatment
Epilepsia·2016· 33 citedOpen Access
Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies
Epilepsy Research·2016· 27 citedOpen Access
Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies
Epilepsy Research·2016· 36 citedOpen Access
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies
Neurology·2016· 110 citedOpen Access
Safety, tolerability, and seizure control during long‐term treatment with adjunctive brivaracetam for partial‐onset seizures
Epilepsia·2016· 71 citedOpen Access
Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome
Neurology·2016· 43 citedOpen Access
Efficacy and Safety of Adjunctive Brivaracetam for Partial-Onset (Focal) Seizures: Pooled Results from Three Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Phase III Studies (P2.022)
Neurology·2016· 3 cited
Efficacy and Safety of Adjunctive Brivaracetam (BRV) for Partial-Onset (Focal) Seizures (POS) in Patients with Type IC Seizures at Baseline: Pooled Results from Three Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies (P2.042)
Neurology·2016· 3 cited
Efficacy of Brivaracetam (BRV) as Adjunctive Therapy in Partial-Onset (Focal) Seizures Among Patients with Prior Levetiracetam (LEV), Carbamazepine (CBZ), Lamotrigine (LTG), or Topiramate (TPM) Exposure (P2.027)
Neurology·2016· 3 cited
Efficacy, Safety, and Tolerability of Brivaracetam (BRV) with Concomitant Lamotrigine (LTG) or Concomitant Topiramate (TPM) in Pooled Phase III Randomized, Double-Blind Trials: A Post Hoc Analysis (P2.041)
Neurology·2016
Post Hoc Analysis of Time to Sustained 50[percnt] Responder Status in Three Phase III Studies of Brivaracetam (BRV) as Adjunctive Treatment for Partial-Onset (Focal) Seizures (POS) (P2.036)
Neurology·2016· 1 cited
page 1 of 2Next →

Frequent Co-authors

Jimmy Schiemann(17), Pavel Klein(12), Martin Johnson(9), Anyzeila Diaz(9), Sami Elmoufti(8), Erwin Surmann(6), Babak Boroojerdi(6), Michael R. Sperling(6), К. Ray Chaudhuri(4), Rūta Mameniškienė(4), Lars Bauer(4), Frank Grieger(4), Claudia Trenkwalder(3), Bryan Kies(3), D. Hill(3), Patrick Kwan(3), Belinda McDonough(3), Klaus Eckhardt(3), Victor Biton(3), William E. Rosenfeld(3)